Laura Richert

Ritonavir-boosted darunavir combined with raltegravir or tenofovir–emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial

François Raffi, Abdel G. Babiker, Laura Richert et al. · The Lancet · 2014 · 176 citations

Pharmacy, Infectious Diseases, Pharmacology +13

Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial

Andrew J. Pollard, Odile Launay, Jean‐Daniel Lelièvre et al. · The Lancet Infectious Diseases · 2020 · 170 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +14

Heterogeneous Escape from X Chromosome Inactivation Results in Sex Differences in Type I IFN Responses at the Single Human pDC Level

Sven Hendrik Hagen, Florian Henseling, Jana Hennesen et al. · Cell Reports · 2020 · 149 citations · Full text

Life Sciences, Genetics, Immunology +17

Cognitive disorders in HIV-infected patients

Fabrice Bonnet, Hélène Amieva, Fabienne Marquant et al. · AIDS · 2012 · 139 citations

Medicine, Neurology, Neuroscience +17

Inducible Bronchus-Associated Lymphoid Tissue Elicited by a Protein Cage Nanoparticle Enhances Protection in Mice against Diverse Respiratory Viruses

James Wiley, Laura Richert, Steve D. Swain et al. · PLoS ONE · 2009 · 130 citations · Full text

Life Sciences, Immunology, Infectious Diseases +17